{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:29:36Z","timestamp":1759580976769,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3690,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.exphem.2012.01.012","type":"journal-article","created":{"date-parts":[[2012,1,21]],"date-time":"2012-01-21T08:16:36Z","timestamp":1327133796000},"page":"359-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Consolidative therapy with stem cell transplantation improves survival of\u00a0patients with mantle cell lymphoma after any induction regimen"],"prefix":"10.1016","volume":"40","author":[{"given":"Nishitha","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adetola","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wichai","family":"Chinratanalab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Englehardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madan H.","family":"Jagasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2012.01.012_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2012.01.012_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2011.04.001","article-title":"Molecular pathogenesis of mantle cell lymphoma: new perspectives and challenges with clinical implications","volume":"48","author":"Navarro","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib3","first-page":"1","article-title":"Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion","volume":"8","author":"Czuczman","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib5","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3109\/10428194.2011.580404","article-title":"Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network","volume":"52","author":"Kenkre","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2012.01.012_bib6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/bmt.2010.77","article-title":"Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?","volume":"45","author":"Nabhan","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.01.012_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.thj.6200007","article-title":"The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients","volume":"1","author":"Dreger","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.exphem.2012.01.012_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdr035","article-title":"Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)","volume":"23","author":"Jantunen","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","article-title":"The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma","volume":"86","author":"Ritchie","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/10428190903026518","article-title":"Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma","volume":"50","author":"Tam","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2012.01.012_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.seminhematol.2011.03.009","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go?","volume":"48","author":"Le Gouill","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib13","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","article-title":"Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901","volume":"17","author":"Shea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.01.012_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced-intensity allogeneic stem cell transplantation (RIC alloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2012.01.012_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.seminhematol.2011.05.001","article-title":"Molecular targeted approaches in mantle cell lymphoma","volume":"48","author":"Weniger","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.01.012_bib17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ajh.21705","article-title":"Validation of the Mantle Cell Lymphoma International Prognostic Index: a single-center retrospective analysis","volume":"85","author":"Smith","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib19","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/j.1349-7006.2011.01988.x","article-title":"Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index","volume":"102","author":"Kimura","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2012.01.012_bib20","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2011.047357","article-title":"Indolent mantle cell lymphoma","volume":"96","author":"Furtado","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2012.01.012_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib22","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib23","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.01.012_bib24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdh069","article-title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis","volume":"15","author":"Mangel","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"van \u2019t Veer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib26","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.01.012_bib27","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2011.06.001","article-title":"Prognostic relevance of clinical risk factors in mantle cell lymphoma","volume":"48","author":"Hoster","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib29","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.01.012_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mdp495","article-title":"Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma","volume":"21","author":"Schaffel","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib31","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":"Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation","volume":"29","author":"Budde","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib32","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.01.012_bib33","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2010-01-263806","article-title":"Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling","volume":"116","author":"Hartmann","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.01.012_bib34","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.01.012_bib35","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib36","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2012.01.012_bib37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2012.01.012_bib38","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12000148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12000148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:29:33Z","timestamp":1759566573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X12000148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0301472X12000148"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2012.01.012","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidative therapy with stem cell transplantation improves survival of\u00a0patients with mantle cell lymphoma after any induction regimen","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2012.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}